Generation Bio Co (NASDAQ: GBIO)’s stock price has decreased by -5.76 compared to its previous closing price of 0.38. However, the company has seen a -7.93% decrease in its stock price over the last five trading sessions. https://www.defenseworld.net reported 2025-06-11 that Squarepoint Ops LLC purchased a new position in Generation Bio Co. (NASDAQ:GBIO – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 65,628 shares of the company’s stock, valued at approximately $70,000. Squarepoint Ops LLC owned approximately 0.10% of Generation Bio as of its most recent SEC filing. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new stake in shares of Generation Bio in the 4th quarter valued at approximately $25,000. Integrated Wealth Concepts LLC acquired a new position in shares of Generation Bio in the 4th quarter worth approximately $77,000. Millennium Management LLC acquired a new position in shares of Generation Bio in the 4th quarter worth approximately $97,000. Deutsche Bank AG raised its holdings in shares of Generation Bio by 688.7% in the 4th quarter. Deutsche Bank AG now owns 184,173 shares of the company’s stock worth $195,000 after buying an additional 160,822 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Generation Bio by 74.9% in the 4th quarter. JPMorgan Chase & Co. now owns 297,705 shares of the company’s stock worth $316,000 after buying an additional 127,513 shares in the last quarter. Institutional investors own 95.22% of the company’s stock. Analysts Set New Price Targets A number of equities analysts have recently issued reports on GBIO shares. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Generation Bio in a report on Thursday, May 8th. Canaccord Genuity Group reissued a “buy” rating and issued a $9.00 target price on shares of Generation Bio in a report on Monday, March 17th. Finally, Wedbush reissued an “outperform” rating and issued a $5.00 target price on shares of Generation Bio in a report on Friday, March 14th. View Our Latest Research Report on Generation Bio Generation Bio Price Performance GBIO stock opened at $0.43 on Wednesday. The business has a fifty day moving average price of $0.39 and a 200 day moving average price of $0.69. Generation Bio Co. has a fifty-two week low of $0.32 and a fifty-two week high of $3.65. The stock has a market capitalization of $28.50 million, a price-to-earnings ratio of -0.19 and a beta of 2.66. Generation Bio (NASDAQ:GBIO – Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%. The firm had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $1.70 million. On average, equities analysts expect that Generation Bio Co. will post -1.75 earnings per share for the current fiscal year. About Generation Bio (Free Report) Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
Is It Worth Investing in Generation Bio Co (NASDAQ: GBIO) Right Now?
The 36-month beta value for GBIO is also noteworthy at 2.66. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for GBIO is 45.82M, and at present, short sellers hold a 2.38% of that float. The average trading volume of GBIO on June 20, 2025 was 512.28K shares.
GBIO’s Market Performance
The stock of Generation Bio Co (GBIO) has seen a -7.93% decrease in the past week, with a -10.40% drop in the past month, and a -33.75% fall in the past quarter. The volatility ratio for the week is 6.14%, and the volatility levels for the past 30 days are at 6.28% for GBIO. The simple moving average for the last 20 days is -6.80% for GBIO stock, with a simple moving average of -68.75% for the last 200 days.
Analysts’ Opinion of GBIO
Canaccord Genuity, on the other hand, stated in their research note that they expect to see GBIO reach a price target of $9. The rating they have provided for GBIO stocks is “Buy” according to the report published on November 08th, 2022.
GBIO Trading at -7.91% from the 50-Day Moving Average
After a stumble in the market that brought GBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.14% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GBIO starting from Quinn Anthony G., who purchase 125,791 shares at the price of $0.96 back on Jan 10 ’25. After this action, Quinn Anthony G. now owns 214,286 shares of Generation Bio Co, valued at $120,759 using the latest closing price.
Quinn Anthony G., the Director of Generation Bio Co, purchase 85,000 shares at $0.97 during a trade that took place back on Jan 13 ’25, which means that Quinn Anthony G. is holding 299,286 shares at $82,450 based on the most recent closing price.
Stock Fundamentals for GBIO
Current profitability levels for the company are sitting at:
- -3.31 for the present operating margin
- 1.0 for the gross margin
The net margin for Generation Bio Co stands at -2.93. The total capital return value is set at -0.45. Equity return is now at value -70.06, with -29.53 for asset returns.
Based on Generation Bio Co (GBIO), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -0.97.
Currently, EBITDA for the company is -74.26 million with net debt to EBITDA at -0.53. When we switch over and look at the enterprise to sales, we see a ratio of 2.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.43.
Conclusion
In summary, Generation Bio Co (GBIO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
